Portland: Worldwide Alumni Club Event with Joseph M. Carroll, PhD
Speaker Event and Reception with Joseph M. Carroll, PhD, Associate Director of Business Development for Knight Cancer Institute at Oregon Health & Science University
Presented by the Columbia Business School Alumni Club of Portland
Wednesday, June 19, 2013 from 5:30 - 7:00 p.m.
Union Bank, 407 SW Broadway, Portland, Oregon 97205
Cost: No cost to attend.
Please join area alumni for an intriguing discussion with Joseph M. Carroll, PhD, Associate Director of Business Development at Knight Cancer Institute. Joseph will discuss the overall process of commercializing medical research discoveries and how medical research institutes such as Knight Cancer Institute partner with industry to facilitate research, license promising discoveries and create new companies. James Perkins, from the Office of Alumni Relations, will attend the event and give an update on the School.
Joseph Carroll has a background in commercializing and translating genomic technologies in various disease settings. Over his 15 year career initiating and managing research efforts in biopharma and biotech (with companies such as Genetics Institute (acquired by Wyeth), Wyeth (acquired by Pfizer) and Millennium P! harmaceuticals), he has worked to utilize genomics to improve drug development and clinical trial design. In 2004, Joseph co-founded a successful (acquired) startup with a researcher at Columbia University (Skinetics Biosciences, Inc.) and moved to oversee research at Sirna Therapeutics (acquired by Merck) after the Skinetics acquisition. After leaving Sirna, Joseph moved to the academic sector including University of Colorado (Boulder, CO), Biomedical Diagnostics Inst. (Dublin, Ireland) to work on facilitating greater academic-industry partnership and new venture creation. In his role managing business development for the Knight Cancer Institute, Joseph helps establish key alliances, partnerships and new ventures to help fulfill Knight’s mission of ending cancer as we know it.
The OHSU Knight Cancer Institute became Oregon’s only NCI-designated cancer center in 1997. The institute is known internationally for its leadership in fighting cancer at the molecular level. The most celebrated cancer discovery in a generation—the targeted drug Gleevec—was developed at OHSU by Brian J. Druker, M.D., the director of the OHSU Knight Cancer Institute and JELD-WEN Chair of Leukemia Research. The institute conducts more than 1,000 research projects and manages approximately 400 clinical trials each year.
Event Parking: Enter Union Bank Tower off SW Broadway. Take far left driveway into Customer Parking. Take yellow ticket and bring to event to be validated. There is no time limit on parking, so please ignore the sign!
To RSVP to attend this event, please email Ty Pettit '75 at Ty.Pettit@unionbank.com.